MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study

已完结 10 由达姆发布于 2026/2/24 14:50:28

DOI:10.1016/s1470-2045(25)00707-7
作者：Fleur M Louis, Anna van der Voort, Mette S van Ramshorst, Antonios Daletzakis, Ingrid A Mandjes, Inge Kemper, Mariette J Agterof, Wim A van der Steeg, Joan B Heijns, Marlies L van Bekkum, Ester J M Si
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundNeoadjuvant treatment comprising six to nine cycles of anti-HER2 based chemotherapy yields high pathological complete response rates and excellent survival outcomes in patients wit

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierCumulative incidence of advanced breast cancer in women aged 40–49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis